List of Braftovi drug patents

Braftovi is owned by Array Biopharma Inc.

Braftovi contains Encorafenib.

Braftovi has a total of 13 drug patents out of which 0 drug patents have expired.

Braftovi was authorised for market use on 27 June, 2018.

Braftovi is available in capsule;oral dosage forms.

Braftovi can be used as braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy, treatment of melanoma with a braf mutation; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test, indicated in combination with binimetinib for the treatment of melanoma with a braf mutation, treatment of melanoma, treatment of melanoma; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy, treatment of melanoma mediated by a b-raf protein kinase; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test, treatment of melanoma; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test.

Drug patent challenges can be filed against Braftovi from June, 2022.

The generics of Braftovi are possible to be released after 05 August, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8946250 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Jul, 2029

(6 years from now)

US8541575 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Feb, 2030

(7 years from now)

US9593099 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US8501758 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Mar, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9850230 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9314464 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Jul, 2031

(8 years from now)

US10258622 ARRAY BIOPHARMA INC Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
Nov, 2032

(9 years from now)

US9387208 ARRAY BIOPHARMA INC Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(9 years from now)

US9763941 ARRAY BIOPHARMA INC Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(9 years from now)

US9474754 ARRAY BIOPHARMA INC Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor
Aug, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025
New Indication (I) Apr 8, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Treatment of melanoma with a braf mutation; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; Braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Treatment of melanoma; Treatment of melanoma mediated by a b-raf protein kinase

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic